Moderna (MRNA) just secured European marketing authorization for mCOMBRIAX, the world’s first combined flu and COVID vaccine for adults 50 and over. This development is putting fresh attention on how this new product might influence the stock.

Despite a 4.95% 1 day share price decline to US$52.85 and a softer 7 day share price return of 3.35%, Moderna’s 30 day and 90 day share price returns of 2.94% and 8.50% indicate recent momentum alongside a 71.26% year to date share price return and a 92.95% 1 year total shareholder return, set against much weaker 3 and 5 year total shareholder returns.

If you are interested in how vaccine names fit into a bigger healthcare theme, it could be worth scanning 34 healthcare AI stocks

With the stock at US$52.85, a value score of 1, analyst targets sitting lower at US$46.10 and the business still reporting losses, is this an undervalued vaccine player or a market already pricing in future growth?

Most Popular Narrative: 69.8% Undervalued

Against the last close at $52.85, the leading narrative pegs Moderna’s fair value at $175.00, a wide gap that puts the spotlight on its pipeline and balance sheet.

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and manufacturing vaccines for the disease at breakneck pace also happened to have bagged a historic windfall in exchange for its performance. Less well-known is how Moderna reinvested the windfall in the wake of its success. The company has spent years plowing its profits into new innovations while maintaining a relatively pristine balance sheet for a company as large as it is. In biotech it is not uncommon for companies to keep low levels of debt. Moderna is unique among its peers for its particularly low valuation relative to its assets. Currently, the company is trading below its book value, with the potential for explosive growth depending on how any one of its numerous drug and treatment investments pan out. Even without any additional investment in medical innovation, the company has a lot of products in its pipeline ready to go.

According to woodworthfund, this fair value hinges on how aggressively that past windfall is recycled into future revenue, along with assumed profitability shifts and a valuation multiple more often associated with mature, high-margin franchises. Curious which pipeline bets and margin paths sit behind that $175.00 figure, and how they stack up against current losses and analyst views.

Result: Fair Value of $175.00 (UNDERVALUED)

However, this depends on Moderna reversing a US$2,822m net loss and a 59.37% three-year total shareholder decline, while also justifying a fair value that is far above analyst targets.

Another View: Market Ratio Says Expensive

That $175.00 fair value from the narrative contrasts with how the stock looks on its current P/S ratio. Moderna trades at 10.8x sales compared with 5.6x for peers and a fair ratio of 1.3x, which points to a rich price and higher valuation risk if sentiment cools.

For context, this gap suggests the market already prices in a lot of future revenue progress, so any setback in execution or pipeline news could matter more than usual for the share price. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With such contrasting signals around value and risk, it helps to look past the headlines, check the underlying data, and decide what truly matters for you. To see what is currently exciting more optimistic investors, review the 1 key reward

Looking for more investment ideas?

If Moderna is on your radar, do not stop there. Use a few focused stock lists to spot other opportunities that could round out your portfolio.

• Target potential mispricings by scanning the 54 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their strengths.
• Prioritize resilience by reviewing the 74 resilient stocks with low risk scores for companies with more stable profiles that could help balance bolder positions.
• Hunt for underfollowed potential by checking the screener containing 23 high quality undiscovered gems that many investors might still be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.